Indian Pharmas Look To Own Brand Extensions In Combo Market
This article was originally published in PharmAsia News
Executive Summary
Indian pharmas are increasingly drawn to applying for brand extensions as they adopt a strategy usually confined to foreign drug makers. The change is due to the popularity of combination drugs in the Indian market, according to a study by ORG IMS. The research firm's report said a third of every new drug launched in India qualify for the term brand extension, accounting for about 18 percent of sales in the country. Analysts see a large increase in brand extensions yet to come as physicians overwhelmed with new products settle for brands they recognize. (Click here for more